Clinical Scorecard: Investigating the Link Between Inflammation and Neurodegeneration: A Pilot Study on a Diagnostic Approach for Multiple Sclerosis Progression
At a Glance
Category
Detail
Condition
Multiple Sclerosis (MS)
Key Mechanisms
Interplay between inflammation and neurodegeneration
Target Population
People with Multiple Sclerosis (PwMS)
Care Setting
Clinical research setting
Key Highlights
Significant thinning of retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) in SPMS compared to RMS.
Elevated levels of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) in PwMS, particularly in SPMS.
CART model achieved approximately 80% accuracy in distinguishing RMS from SPMS using biomarkers.
Guideline-Based Recommendations
Diagnosis
Utilize multimodal biomarkers including sNfL, GCIPL thickness, and monocyte subsets for MS progression assessment.
Management
Tailor therapeutic interventions based on identified biomarkers to optimize treatment strategies.
Monitoring & Follow-up
Regular assessment of neurodegenerative markers and retinal changes to monitor disease progression.
Risks
Conventional therapies may not effectively prevent long-term disability in progressive MS.
Patient & Prescribing Data
Patients with relapsing and secondary progressive MS.
Identifying biomarkers for PIRA is critical for improving treatment strategies.
Clinical Best Practices
Integrate inflammatory and neurodegenerative biomarkers for accurate MS progression diagnosis.
Employ non-invasive tools like OCT and mfERG for retinal assessment.
by Tobias Hegelmaier, Khaldoon O. Al-Nosairy, Alexander Duscha, Antonia Lipp, Henrike Marie Nowitzki, Christiane Desel, Shahram Taherzadeh Amlashi, Léon Beyer, Klaus Gerwert, Hagen Thieme, Michael B. Hoffmann, Aiden Haghikia
